Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research and Development Ltd
Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Estudio clínico de fase II, doble ciego, explorador, de grupos paralelos y controlado con placebo para evaluar dos pautas posológicas de GSK2402968 para la eficacia, seguridad, tolerabilidad y farmacocinética en sujetos ambulatorios con distrofia muscular de Duchenne
- Evaluar la eficacia de 2 pautas posológicas diferentes de GSK2402968 administrado por vía subcutánea durante 24 semanas en sujetos ambulatorios con DMD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy
To evaluate the long term safety, tolerability and efficacy of subcutaneous 6mg/kg/week GSK2402968 in subjects with DMD who have participated in either DMD114117 or DMD114044.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD)
To evaluate the effects of 12 weeks of treatment with GW856553 7.5 mg BID compared with placebo on the percentage of sputum neutrophils at 12 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma
To evaluate the efficacy of repeat intravenous dose administration of GSK679586 in patients with severe asthma
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y con un fármaco activo y de grupos paralelos para determinar la eficacia y la seguridad de albiglutida administrada en combinación con metformina, en comparación con metformina más sitagliptina, metformina más glimepirida y metformina más placebo en sujetos con diabetes mellitus de tipo 2 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus
El objetivo principal del estudio consiste en evaluar la eficacia de la albiglutida administrada en combinación con metformina en comparación con metformina + sitagliptina, metformina + glimepirida y ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
The primary objective of this study is to demonstrate the superiority of 30 mg intravenous GW679769, in combination with a single 4 mg intravenous dose of ZOFRAN (ondansetron hydrochloride), over a si...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Clinical study using the drug GSK525762 in Subjects with cancer
- To determine the safety, tolerability and maximum tolerated dose (MTD) of GSK525762 in subjects 16 years or older following QD and/or BID dosing schedules. - To evaluate the clinical activity of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism following Total Knee Replacement Surgery
The primary objective of the trial is to assess the safety and efficacy of odiparcil in the prevention of VTE following TKR and to provide evidence to enable the selection of a single dose of odiparci...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A study to test two investigational drugs, dabrafenib and trametinib, in combination together for treating a specific type of melanoma compared to another drug, vemurafenib that is approved for treatingthe same type of melanoma
• To establish the superiority of dabrafenib and trametinib combination therapy with vemurafenib monotherapy with respect to overall survival (OS) for subjects with advanced/metastatic BRAF V600E/K m...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors or Leukemia
The primary objective of the study is to provide continued treatment with GSK1120212 for subjects who have previously participated in a GSK1120212 study and who continue to receive clinical benefit as...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant